NASDAQ:KPTI - Karyopharm Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$17.90 -1.16 (-6.09 %)
(As of 05/24/2018 01:55 PM ET)
Previous Close$18.30
Today's Range$16.82 - $18.30
52-Week Range$7.48 - $20.39
Volume35,050 shs
Average Volume1.39 million shs
Market Capitalization$938.18 million
P/E Ratio-6.38
Dividend YieldN/A
Beta3.62

About Karyopharm Therapeutics (NASDAQ:KPTI)

Karyopharm Therapeutics logoKaryopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma. The company is also developing KPT-8602 that is in Phase 1/2 study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.

Receive KPTI News and Ratings via Email

Sign-up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KPTI
CUSIPN/A
Phone617-658-0600

Debt

Debt-to-Equity RatioN/A
Current Ratio2.85
Quick Ratio2.85

Price-To-Earnings

Trailing P/E Ratio-6.38
Forward P/E Ratio-5.68
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.61 million
Price / Sales554.23
Cash FlowN/A
Price / CashN/A
Book Value$1.92 per share
Price / Book9.32

Profitability

EPS (Most Recent Fiscal Year)($2.81)
Net Income$-128,980,000.00
Net MarginsN/A
Return on Equity-103.24%
Return on Assets-81.36%

Miscellaneous

Employees154
Outstanding Shares49,850,000

Karyopharm Therapeutics (NASDAQ:KPTI) Frequently Asked Questions

What is Karyopharm Therapeutics' stock symbol?

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

How were Karyopharm Therapeutics' earnings last quarter?

Karyopharm Therapeutics (NASDAQ:KPTI) posted its quarterly earnings data on Thursday, May, 10th. The company reported ($0.78) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.67) by $0.11. The business had revenue of $10 million for the quarter, compared to analyst estimates of $4.59 million. View Karyopharm Therapeutics' Earnings History.

When is Karyopharm Therapeutics' next earnings date?

Karyopharm Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Karyopharm Therapeutics.

What price target have analysts set for KPTI?

9 brokers have issued twelve-month price targets for Karyopharm Therapeutics' shares. Their predictions range from $18.00 to $30.00. On average, they expect Karyopharm Therapeutics' stock price to reach $21.7778 in the next year. View Analyst Ratings for Karyopharm Therapeutics.

What are Wall Street analysts saying about Karyopharm Therapeutics stock?

Here are some recent quotes from research analysts about Karyopharm Therapeutics stock:
  • 1. According to Zacks Investment Research, "Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. " (5/17/2018)
  • 2. Cantor Fitzgerald analysts commented, "KPTI reported top-line STORM data, which demonstrated a 25.4% ORR (2 CRs and 19 PRs) and 4.4 months DoR in penta-refractory myeloma patients. That means the company will be able to file an NDA for accelerated approval in this population in the U.S. and Europe." (4/30/2018)
  • 3. Canaccord Genuity analysts commented, "We had the pleasure of hosting Karyopharm CEO Michael Kauffman and CFO Mike Falvey for meetings with institutional investors in New York City. Overall, investors focused on upcoming and potentially registration-supporting datasets for lead drug candidate selinexor in two trials: STORM in penta-refractory multiple myeloma (April 30) and SADAL in relapsed/refractory diffuse large B-cell lymphoma (DLBCL, 2H). We came away with increased confidence that Accelerated Approval is a viable path for selinexor, continue to view the available data as indicative of benefit, and reiterate our BUY rating and $22 PT." (4/10/2018)

Are investors shorting Karyopharm Therapeutics?

Karyopharm Therapeutics saw a increase in short interest in April. As of April 30th, there was short interest totalling 3,555,503 shares, an increase of 38.0% from the April 13th total of 2,576,427 shares. Based on an average trading volume of 735,525 shares, the short-interest ratio is presently 4.8 days. Currently, 9.5% of the company's shares are short sold.

Who are some of Karyopharm Therapeutics' key competitors?

Who are Karyopharm Therapeutics' key executives?

Karyopharm Therapeutics' management team includes the folowing people:
  • Dr. Michael G. Kauffman, Co-Founder, CEO & Director (Age 55)
  • Dr. Sharon Shacham, Co-Founder, Co-Chairman of Scientific Advisory Board, Pres & Chief Scientific Officer (Age 48)
  • Dr. Mansoor Raza Mirza, Clinical Consultant, Director and Member of Scientific Advisory Board (Age 57)
  • Mr. Michael F. Falvey, Exec. VP, CFO & Treasurer (Age 59)
  • Mr. Ran Frenkel, Chief Devel. Operations Officer (Age 49)

Has Karyopharm Therapeutics been receiving favorable news coverage?

Media headlines about KPTI stock have trended somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Karyopharm Therapeutics earned a media sentiment score of 0.12 on Accern's scale. They also gave news coverage about the company an impact score of 46.66 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are Karyopharm Therapeutics' major shareholders?

Karyopharm Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Palo Alto Investors LP (7.38%), BlackRock Inc. (5.55%), Franklin Resources Inc. (4.13%), Point72 Asset Management L.P. (3.93%), venBio Select Advisor LLC (1.12%) and Northern Trust Corp (0.80%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman, Ran Frenkel and Sharon Shacham. View Institutional Ownership Trends for Karyopharm Therapeutics.

Which major investors are selling Karyopharm Therapeutics stock?

KPTI stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Franklin Resources Inc., Candriam Luxembourg S.C.A., Iguana Healthcare Management LLC, Opus Point Partners Management LLC, A.R.T. Advisors LLC and JPMorgan Chase & Co.. Company insiders that have sold Karyopharm Therapeutics company stock in the last year include Christopher Brett Primiano, Mansoor Raza Mirza, Michael Kauffman and Sharon Shacham. View Insider Buying and Selling for Karyopharm Therapeutics.

Which major investors are buying Karyopharm Therapeutics stock?

KPTI stock was bought by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Doheny Asset Management CA, Palo Alto Investors LP, BlackRock Inc., Prudential Financial Inc., Trexquant Investment LP, Cubist Systematic Strategies LLC and DekaBank Deutsche Girozentrale. View Insider Buying and Selling for Karyopharm Therapeutics.

How do I buy shares of Karyopharm Therapeutics?

Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Karyopharm Therapeutics' stock price today?

One share of KPTI stock can currently be purchased for approximately $17.94.

How big of a company is Karyopharm Therapeutics?

Karyopharm Therapeutics has a market capitalization of $938.18 million and generates $1.61 million in revenue each year. The company earns $-128,980,000.00 in net income (profit) each year or ($2.81) on an earnings per share basis. Karyopharm Therapeutics employs 154 workers across the globe.

How can I contact Karyopharm Therapeutics?

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at 617-658-0600 or via email at [email protected]


MarketBeat Community Rating for Karyopharm Therapeutics (KPTI)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  311 (Vote Outperform)
Underperform Votes:  170 (Vote Underperform)
Total Votes:  481
MarketBeat's community ratings are surveys of what our community members think about Karyopharm Therapeutics and other stocks. Vote "Outperform" if you believe KPTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KPTI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Karyopharm Therapeutics (NASDAQ:KPTI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
9 Wall Street analysts have issued ratings and price targets for Karyopharm Therapeutics in the last 12 months. Their average twelve-month price target is $21.7778, suggesting that the stock has a possible upside of 21.66%. The high price target for KPTI is $30.00 and the low price target for KPTI is $18.00. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.893.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $21.7778$21.00$17.4286$17.4286
Price Target Upside: 21.66% upside54.19% upside66.78% upside65.36% upside

Karyopharm Therapeutics (NASDAQ:KPTI) Consensus Price Target History

Price Target History for Karyopharm Therapeutics (NASDAQ:KPTI)

Karyopharm Therapeutics (NASDAQ:KPTI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/24/2018WedbushDowngradeOutperform ➝ Neutral$20.00 ➝ $19.00HighView Rating Details
5/17/2018HC WainwrightReiterated RatingBuy$30.00LowView Rating Details
5/1/2018Leerink SwannReiterated RatingOutperform$19.00 ➝ $24.00HighView Rating Details
4/30/2018Cantor FitzgeraldSet Price TargetBuy$18.00HighView Rating Details
4/25/2018Jefferies GroupReiterated RatingBuyMediumView Rating Details
4/10/2018Canaccord GenuityReiterated RatingBuy$22.00LowView Rating Details
4/10/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$19.00 ➝ $20.00HighView Rating Details
3/15/2018Robert W. BairdSet Price TargetBuy$22.00MediumView Rating Details
3/2/2018Royal Bank of CanadaReiterated RatingBuy$22.00HighView Rating Details
8/30/2016S&P Equity ResearchLower Price Target$9.06 ➝ $7.55N/AView Rating Details
5/27/2016Raymond JamesInitiated CoverageOutperform$13.00N/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Karyopharm Therapeutics (NASDAQ:KPTI) Earnings History and Estimates Chart

Earnings by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Karyopharm Therapeutics (NASDAQ:KPTI) Earnings Estimates

2018 EPS Consensus Estimate: ($2.90)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.74)($0.51)($0.63)
Q2 20183($0.82)($0.65)($0.75)
Q3 20183($0.86)($0.65)($0.74)
Q4 20183($0.91)($0.67)($0.79)

Karyopharm Therapeutics (NASDAQ KPTI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018($0.83)N/AView Earnings Details
5/10/2018Q1 2018($0.67)($0.78)$4.59 million$10.00 millionViewN/AView Earnings Details
3/15/2018Q4 2017($0.66)($0.80)$2.26 million$1.53 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.64)($0.65)$0.03 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.64)($0.64)$0.23 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.6670)($0.71)$0.02 million$0.07 millionViewListenView Earnings Details
3/16/2017Q4 2016($0.65)($0.65)$0.18 million$0.05 millionViewN/AView Earnings Details
11/7/2016Q316($0.81)($0.69)$0.18 million$0.05 millionViewListenView Earnings Details
8/4/2016Q216($0.76)($0.84)$0.18 million$0.06 millionViewN/AView Earnings Details
5/9/2016Q116($0.74)($0.75)$0.30 millionViewN/AView Earnings Details
3/14/2016Q415($0.82)($0.81)$0.30 million$0.03 millionViewListenView Earnings Details
11/9/2015Q315($0.87)($0.85)$0.30 million$0.08 millionViewListenView Earnings Details
8/10/2015Q215($0.77)($0.92)$0.30 million$0.15 millionViewListenView Earnings Details
5/11/2015Q115($0.75)($0.74)$0.30 millionViewListenView Earnings Details
3/16/2015Q414($0.66)($0.79)$0.11 million$0.02 millionViewListenView Earnings Details
11/10/2014Q314($0.53)($0.61)$0.20 million$0.02 millionViewN/AView Earnings Details
8/7/2014Q214($0.51)($0.55)$0.20 million$0.02 millionViewN/AView Earnings Details
5/7/2014Q1 2014($0.45)($0.46)$0.25 million$0.17 millionViewN/AView Earnings Details
3/5/2014($0.34)($2.00)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Karyopharm Therapeutics (NASDAQ:KPTI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Karyopharm Therapeutics (NASDAQ KPTI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.26%
Institutional Ownership Percentage: 61.44%
Insider Trading History for Karyopharm Therapeutics (NASDAQ:KPTI)
Institutional Ownership by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Karyopharm Therapeutics (NASDAQ KPTI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/18/2018Michael KauffmanCEOSell10,000$19.39$193,900.00View SEC Filing  
5/10/2018Christopher Brett PrimianoEVPSell2,000$18.01$36,020.00675View SEC Filing  
5/7/2018Sharon ShachamInsiderSell10,000$16.77$167,700.00View SEC Filing  
4/18/2018Michael KauffmanCEOSell10,000$14.79$147,900.00522,143View SEC Filing  
4/9/2018Sharon ShachamInsiderSell10,000$12.48$124,800.00723,510View SEC Filing  
3/19/2018Michael KauffmanCEOSell10,000$15.29$152,900.00522,143View SEC Filing  
3/12/2018Mansoor Raza MirzaDirectorSell2,500$17.01$42,525.002,500View SEC Filing  
3/7/2018Sharon ShachamInsiderSell10,000$16.15$161,500.00723,510View SEC Filing  
3/5/2018Christopher Brett PrimianoEVPSell2,500$16.03$40,075.004,881View SEC Filing  
2/20/2018Michael KauffmanCEOSell10,000$14.79$147,900.00View SEC Filing  
2/16/2018Christopher Brett PrimianoEVPSell2,500$15.01$37,525.00View SEC Filing  
2/7/2018Christopher Brett PrimianoEVPSell1,500$13.00$19,500.009,881View SEC Filing  
2/7/2018Sharon ShachamInsiderSell10,000$12.50$125,000.00723,510View SEC Filing  
1/18/2018Michael KauffmanCEOSell10,000$10.09$100,900.00522,143View SEC Filing  
1/8/2018Sharon ShachamInsiderSell10,000$10.08$100,800.00723,510View SEC Filing  
12/18/2017Michael KauffmanCEOSell10,000$9.16$91,600.00522,143View SEC Filing  
12/12/2017Christopher Brett PrimianoSVPSell27,042$10.28$277,991.7611,381View SEC Filing  
12/7/2017Sharon ShachamInsiderSell10,000$10.39$103,900.00View SEC Filing  
11/7/2017Christopher Brett PrimianoSVPSell4,958$11.25$55,777.50View SEC Filing  
10/2/2017Christopher Brett PrimianoSVPSell1,500$12.00$18,000.00View SEC Filing  
10/2/2017Mansoor Raza MirzaDirectorSell2,000$12.00$24,000.00View SEC Filing  
9/15/2017Christopher Brett PrimianoSVPSell2,000$11.00$22,000.0012,881View SEC Filing  
9/15/2017Mansoor Raza MirzaDirectorSell2,882$11.00$31,702.002,882View SEC Filing  
9/11/2017Mansoor Raza MirzaDirectorSell118$11.00$1,298.00118View SEC Filing  
8/29/2017Christopher Brett PrimianoSVPSell2,195$10.00$21,950.00View SEC Filing  
6/26/2017Christopher Brett PrimianoSVPSell805$10.03$8,074.15View SEC Filing  
11/14/2016Ran FrenkelInsiderSell3,309$10.06$33,288.5414,691View SEC Filing  
6/23/2016Ltd ChioneMajor ShareholderSell18,824$8.03$151,156.72View SEC Filing  
6/13/2016Ltd ChioneMajor ShareholderSell7,074$8.51$60,199.748,568,744View SEC Filing  
6/9/2016Ltd ChioneMajor ShareholderSell45,541$9.21$419,432.618,605,818View SEC Filing  
6/7/2016Ltd ChioneMajor ShareholderSell40,000$9.24$369,600.008,641,359View SEC Filing  
6/2/2016Ltd ChioneMajor ShareholderSell17,855$9.65$172,300.758,661,359View SEC Filing  
6/1/2016Ltd ChioneMajor ShareholderSell74,664$9.61$717,521.048,713,878View SEC Filing  
5/31/2016Ltd ChioneMajor ShareholderSell17,096$9.66$165,147.368,713,878View SEC Filing  
5/27/2016Ltd ChioneMajor ShareholderSell40,000$9.58$383,200.008,713,878View SEC Filing  
5/26/2016Ltd ChioneMajor ShareholderSell46,122$9.73$448,767.068,772,060View SEC Filing  
5/23/2016Ltd ChioneMajor ShareholderSell93,932$8.54$802,179.288,873,932View SEC Filing  
5/18/2016Ltd ChioneMajor ShareholderSell63,800$8.15$519,970.008,923,932View SEC Filing  
5/16/2016Ltd ChioneMajor ShareholderSell10,400$8.01$83,304.008,967,732View SEC Filing  
5/11/2016Ltd ChioneMajor ShareholderSell31,868$8.24$262,592.328,980,000View SEC Filing  
12/8/2015Mansoor Raza MirzaDirectorSell15,000$15.01$225,150.00View SEC Filing  
4/7/2015Ran FrenkelEVPBuy3,000$31.81$95,430.00View SEC Filing  
4/2/2015Barry E GreeneDirectorBuy3,000$29.31$87,930.00View SEC Filing  
4/2/2015Justin A RenzCFOBuy5,000$29.71$148,550.00View SEC Filing  
1/12/2015Deepika PakianathanDirectorBuy45,454$33.00$1,499,982.00View SEC Filing  
1/12/2015Michael KauffmanCEOSell50,000$33.00$1,650,000.00View SEC Filing  
1/12/2015Sharon ShachamInsiderSell25,000$33.00$825,000.00View SEC Filing  
12/2/2014Mansoor Raza MirzaDirectorSell10,000$43.52$435,200.00View SEC Filing  
12/1/2014Ltd ChioneMajor ShareholderSell278,115$41.92$11,658,580.80View SEC Filing  
11/25/2014Ltd ChioneMajor ShareholderSell242,800$42.40$10,294,720.00View SEC Filing  
11/19/2014Ltd ChioneMajor ShareholderSell65,968$40.09$2,644,657.12View SEC Filing  
11/12/2014Ltd ChioneMajor ShareholderSell164,100$42.83$7,028,403.00View SEC Filing  
11/11/2014Ltd ChioneMajor ShareholderSell54,100$42.51$2,299,791.00View SEC Filing  
11/10/2014Ltd ChioneMajor ShareholderSell65,000$43.40$2,821,000.00View SEC Filing  
11/10/2014Mansoor Raza MirzaDirectorSell5,000$45.05$225,250.00View SEC Filing  
11/6/2014Ltd ChioneMajor ShareholderSell272,784$42.11$11,486,934.24View SEC Filing  
10/29/2014Mansoor Raza MirzaDirectorSell3,500$40.05$140,175.00View SEC Filing  
9/26/2014Marcin CzernikMajor ShareholderSell50,000$42.54$2,127,000.00View SEC Filing  
9/24/2014Marcin CzernikMajor ShareholderSell22,498$40.32$907,119.36View SEC Filing  
9/18/2014Marcin CzernikMajor ShareholderSell12,347$40.24$496,843.28View SEC Filing  
9/17/2014Marcin CzernikMajor ShareholderSell9,569$40.26$385,247.94View SEC Filing  
9/12/2014Ltd ChioneMajor ShareholderSell4,312$41.12$177,309.44View SEC Filing  
9/8/2014Marcin CzernikMajor ShareholderSell35,666$39.92$1,423,786.72View SEC Filing  
9/4/2014Marcin CzernikMajor ShareholderSell12,795$38.07$487,105.65View SEC Filing  
8/27/2014Marcin CzernikMajor ShareholderSell43,699$38.80$1,695,521.20View SEC Filing  
8/25/2014Marcin CzernikMajor ShareholderSell4,389$38.08$167,133.12View SEC Filing  
8/15/2014Marcin CzernikMajor ShareholderSell8,027$39.11$313,935.97View SEC Filing  
8/11/2014Marcin CzernikMajor ShareholderSell36,979$37.30$1,379,316.70View SEC Filing  
7/30/2014Marcin CzernikMajor ShareholderSell21,570$36.20$780,834.00View SEC Filing  
7/29/2014Ltd ChioneMajor ShareholderSell30,000$35.20$1,056,000.00View SEC Filing  
7/23/2014Ltd PlioInsiderSell500,000$35.54$17,770,000.00View SEC Filing  
7/2/2014Michael KauffmanCEOSell200,000$42.50$8,500,000.00View SEC Filing  
6/18/2014Sharon ShachamInsiderSell20,000$41.76$835,200.00View SEC Filing  
6/17/2014Michael KauffmanCEOSell20,000$41.76$835,200.00View SEC Filing  
5/23/2014Deepika PakianathanDirectorBuy114,419$26.18$2,995,489.42View SEC Filing  
5/13/2014Paul BrannellySVPBuy1,000$28.06$28,060.0064,636View SEC Filing  
11/12/2013Deepika PakianathanDirectorBuy312,500$16.00$5,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Karyopharm Therapeutics (NASDAQ KPTI) News Headlines

Source:
DateHeadline
Karyopharm Therapeutics (KPTI) Downgraded to "Neutral" at WedbushKaryopharm Therapeutics (KPTI) Downgraded to "Neutral" at Wedbush
www.americanbankingnews.com - May 24 at 1:14 PM
Karyopharm Therapeutics (KPTI) Forecasted to Earn FY2018 Earnings of ($2.67) Per ShareKaryopharm Therapeutics (KPTI) Forecasted to Earn FY2018 Earnings of ($2.67) Per Share
www.americanbankingnews.com - May 24 at 8:36 AM
Karyopharm inks product commercialization deal in China valued at up to $162MKaryopharm inks product commercialization deal in China valued at up to $162M
seekingalpha.com - May 24 at 8:20 AM
Karyopharm and Antengene Sign Exclusive License Agreement to Develop and Commercialize Selinexor, Eltanexor, Verdinexor and KPT-9274 in China and Other Regions in AsiaKaryopharm and Antengene Sign Exclusive License Agreement to Develop and Commercialize Selinexor, Eltanexor, Verdinexor and KPT-9274 in China and Other Regions in Asia
finance.yahoo.com - May 24 at 8:20 AM
Karyopharm Therapeutics Expected to Post FY2019 Earnings of ($2.43) Per Share (KPTI)Karyopharm Therapeutics Expected to Post FY2019 Earnings of ($2.43) Per Share (KPTI)
www.americanbankingnews.com - May 23 at 7:38 AM
Insider Selling: Karyopharm Therapeutics (KPTI) CEO Sells 10,000 Shares of StockInsider Selling: Karyopharm Therapeutics (KPTI) CEO Sells 10,000 Shares of Stock
www.americanbankingnews.com - May 21 at 7:54 PM
Karyopharm Therapeutics (KPTI) Expected to Post Earnings of -$0.82 Per ShareKaryopharm Therapeutics (KPTI) Expected to Post Earnings of -$0.82 Per Share
www.americanbankingnews.com - May 21 at 11:10 AM
Jefferies Group Analysts Reduce Earnings Estimates for Karyopharm Therapeutics (KPTI)Jefferies Group Analysts Reduce Earnings Estimates for Karyopharm Therapeutics (KPTI)
www.americanbankingnews.com - May 18 at 7:37 AM
Karyopharm Therapeutics (KPTI) to Present Selinexor Phase 1b/2 STOMP Data at EHAKaryopharm Therapeutics (KPTI) to Present Selinexor Phase 1b/2 STOMP Data at EHA
www.streetinsider.com - May 17 at 6:38 PM
Karyopharm to Present Selinexor Phase 1b/2 STOMP Data at the European Hematology Association 2018 Annual MeetingKaryopharm to Present Selinexor Phase 1b/2 STOMP Data at the European Hematology Association 2018 Annual Meeting
finance.yahoo.com - May 17 at 6:38 PM
BidaskClub Upgrades Karyopharm Therapeutics (KPTI) to "Strong-Buy"BidaskClub Upgrades Karyopharm Therapeutics (KPTI) to "Strong-Buy"
www.americanbankingnews.com - May 17 at 5:50 PM
Karyopharm Therapeutics (KPTI) Upgraded by Zacks Investment Research to "Hold"Karyopharm Therapeutics (KPTI) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - May 17 at 4:59 PM
HC Wainwright Reiterates "Buy" Rating for Karyopharm Therapeutics (KPTI)HC Wainwright Reiterates "Buy" Rating for Karyopharm Therapeutics (KPTI)
www.americanbankingnews.com - May 17 at 2:51 PM
Karyopharm Therapeutics (KPTI) to Present Selinexor Phase 2 SEAL Data at ASCOKaryopharm Therapeutics (KPTI) to Present Selinexor Phase 2 SEAL Data at ASCO
www.streetinsider.com - May 17 at 8:22 AM
Wedbush Comments on Karyopharm Therapeutics FY2022 Earnings (KPTI)Wedbush Comments on Karyopharm Therapeutics' FY2022 Earnings (KPTI)
www.americanbankingnews.com - May 14 at 5:11 AM
Leerink Swann Brokers Cut Earnings Estimates for Karyopharm Therapeutics (KPTI)Leerink Swann Brokers Cut Earnings Estimates for Karyopharm Therapeutics (KPTI)
www.americanbankingnews.com - May 14 at 2:16 AM
Short Interest in Karyopharm Therapeutics (KPTI) Increases By 38.0%Short Interest in Karyopharm Therapeutics (KPTI) Increases By 38.0%
www.americanbankingnews.com - May 13 at 2:28 AM
Form SC 13G/A Karyopharm Therapeutics Filed by: FMR LLCForm SC 13G/A Karyopharm Therapeutics Filed by: FMR LLC
www.streetinsider.com - May 12 at 5:53 PM
Karyopharm Therapeutics Inc.Karyopharm Therapeutics Inc.
www.streetinsider.com - May 12 at 5:53 PM
BRIEF-Karyopharm Therapeutics Reports Q1 Loss Per Share Of $0.78BRIEF-Karyopharm Therapeutics Reports Q1 Loss Per Share Of $0.78
www.reuters.com - May 12 at 5:53 PM
Karyopharm Therapeutics (KPTI) Releases Quarterly  Earnings Results, Misses Expectations By $0.11 EPSKaryopharm Therapeutics (KPTI) Releases Quarterly Earnings Results, Misses Expectations By $0.11 EPS
www.americanbankingnews.com - May 12 at 2:40 PM
Karyopharm Therapeutics (KPTI) PT Raised to $24 at RBC Capital; We Would Be BuyersKaryopharm Therapeutics (KPTI) PT Raised to $24 at RBC Capital; 'We Would Be Buyers'
www.streetinsider.com - May 11 at 5:58 PM
Edited Transcript of KPTI earnings conference call or presentation 10-May-18 12:30pm GMTEdited Transcript of KPTI earnings conference call or presentation 10-May-18 12:30pm GMT
finance.yahoo.com - May 11 at 8:28 AM
Karyopharm Therapeutics (KPTI) EVP Sells $36,020.00 in StockKaryopharm Therapeutics (KPTI) EVP Sells $36,020.00 in Stock
www.americanbankingnews.com - May 10 at 8:33 PM
Karyopharm Therapeutics misses by $0.16, beats on revenueKaryopharm Therapeutics misses by $0.16, beats on revenue
seekingalpha.com - May 10 at 8:25 AM
Karyopharm Reports First Quarter 2018 Financial Results and Highlights Recent ProgressKaryopharm Reports First Quarter 2018 Financial Results and Highlights Recent Progress
finance.yahoo.com - May 10 at 8:25 AM
Karyopharm Therapeutics: 1Q Earnings SnapshotKaryopharm Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 8:25 AM
Karyopharm Therapeutics (KPTI) Insider Sharon Shacham Sells 10,000 SharesKaryopharm Therapeutics (KPTI) Insider Sharon Shacham Sells 10,000 Shares
www.americanbankingnews.com - May 8 at 7:57 PM
Karyopharm Therapeutics Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional SharesKaryopharm Therapeutics Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - May 7 at 5:38 PM
Reader Inquiry: Is Karyopharm Therapeutics A Buy After The Secondary Offering?Reader Inquiry: Is Karyopharm Therapeutics A Buy After The Secondary Offering?
seekingalpha.com - May 7 at 8:20 AM
$4.59 Million in Sales Expected for Karyopharm Therapeutics (KPTI) This Quarter$4.59 Million in Sales Expected for Karyopharm Therapeutics (KPTI) This Quarter
www.americanbankingnews.com - May 6 at 7:45 AM
Karyopharm Therapeutics (KPTI) Scheduled to Post Earnings on ThursdayKaryopharm Therapeutics (KPTI) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - May 5 at 10:51 AM
Karyopharm Therapeutics (KPTI) Upgraded by BidaskClub to "Buy"Karyopharm Therapeutics (KPTI) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - May 5 at 12:11 AM
 Analysts Anticipate Karyopharm Therapeutics (KPTI) to Post -$0.67 EPS Analysts Anticipate Karyopharm Therapeutics (KPTI) to Post -$0.67 EPS
www.americanbankingnews.com - May 4 at 3:20 AM
Karyopharm Therapeutics (KPTI) Rating Increased to Hold at ValuEngineKaryopharm Therapeutics (KPTI) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - May 3 at 11:51 PM
KaryoPharma Therapeutics: A Strong Horse In A Weak MarketKaryoPharma Therapeutics: A Strong Horse In A Weak Market
seekingalpha.com - May 3 at 5:24 PM
Leerink Swann Weighs in on Karyopharm Therapeutics FY2019 Earnings (KPTI)Leerink Swann Weighs in on Karyopharm Therapeutics' FY2019 Earnings (KPTI)
www.americanbankingnews.com - May 3 at 9:57 AM
UPDATE: Karyopharm (KPTI) Says Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma Achieved 25.4% ORRUPDATE: Karyopharm (KPTI) Says Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma Achieved 25.4% ORR
www.streetinsider.com - May 3 at 8:17 AM
Karyopharm to Report First Quarter 2018 Financial Results on May 10, 2018Karyopharm to Report First Quarter 2018 Financial Results on May 10, 2018
finance.yahoo.com - May 3 at 8:17 AM
Karyopharm Therapeutics (KPTI) Forecasted to Earn Q1 2018 Earnings of ($0.51) Per ShareKaryopharm Therapeutics (KPTI) Forecasted to Earn Q1 2018 Earnings of ($0.51) Per Share
www.americanbankingnews.com - May 3 at 7:04 AM
Karyopharm Therapeutics (KPTI) Commences $125M Common Stock OfferingKaryopharm Therapeutics (KPTI) Commences $125M Common Stock Offering
www.streetinsider.com - May 2 at 8:21 AM
Biotechnology Movers: Karyopharm Therapeutics Inc. and Regeneron PharmaceuticalsBiotechnology Movers: Karyopharm Therapeutics Inc. and Regeneron Pharmaceuticals
finance.yahoo.com - May 1 at 5:18 PM
Karyopharm launches $125M stock offering; shares down 3% after hoursKaryopharm launches $125M stock offering; shares down 3% after hours
seekingalpha.com - May 1 at 5:18 PM
Karyopharm Therapeutics Announces Proposed Public Offering of Common StockKaryopharm Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - May 1 at 5:18 PM
Why Karyopharm Therapeutics Inc. Shares Are Soaring 15% TodayWhy Karyopharm Therapeutics Inc. Shares Are Soaring 15% Today
www.fool.com - May 1 at 1:35 PM
Karyopharm Therapeutics (KPTI) "Outperform" Rating Reaffirmed at Leerink SwannKaryopharm Therapeutics' (KPTI) "Outperform" Rating Reaffirmed at Leerink Swann
www.americanbankingnews.com - May 1 at 10:00 AM
Karyopharm Impresses In Refractory Multiple Myeloma TrialKaryopharm Impresses In Refractory Multiple Myeloma Trial
seekingalpha.com - May 1 at 8:26 AM
Newton’s Karyopharm to seek FDA approval for cancer drug after trial winNewton’s Karyopharm to seek FDA approval for cancer drug after trial win
finance.yahoo.com - May 1 at 8:26 AM
Karyopharm Therapeutics (KPTI) Rating Reiterated by Cantor FitzgeraldKaryopharm Therapeutics (KPTI) Rating Reiterated by Cantor Fitzgerald
www.americanbankingnews.com - April 30 at 9:10 PM
Karyopharms selinexor shows treatment effect in mid-stage myeloma study; shares up 22% after hoursKaryopharm's selinexor shows treatment effect in mid-stage myeloma study; shares up 22% after hours
seekingalpha.com - April 30 at 5:14 PM

SEC Filings

Karyopharm Therapeutics (NASDAQ:KPTI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Karyopharm Therapeutics (NASDAQ:KPTI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Karyopharm Therapeutics (NASDAQ KPTI) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.